GLP-1 Vision Loss Lawsuits: About 3 Extra Cases per 10,000
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
A rare form of sudden vision loss called NAION is back in the news because lawsuits over it have been consolidated in a federal court. The underlying research is two years old, European regulators added a warning in 2025, and the best current estimate is roughly three extra cases per 10,000 people treated.
Who This Helps
This is for you if you've seen a lawyer's advertisement or a headline about blindness and want to know what the number actually is. Our broader piece on long-term GLP-1 side effects covers where this sits among everything else.
What the condition is
NAION stands for non-arteritic anterior ischemic optic neuropathy. The UK regulator describes it as a condition that "typically causes sudden, painless vision loss, usually in one eye," caused by "reduced blood flow to the front portion of the optic nerve" (MHRA). It's usually permanent and usually affects one eye rather than both.
It also happens to people who've never taken any of these medications. The same regulatory document puts background incidence at between 7.73 and 11.35 cases per 100,000 people per year in adults over 40. More importantly for reading any of this research: "patients with type 2 diabetes are at increased risk of NAION as a result of their condition." This means much of the research studies a diabetes drug in people who already have diabetes, and are already at higher risk of the condition.
The number worth carrying around
Relative risk makes headlines. Absolute risk tells you whether to worry.
A 2026 US claims study followed adults with type 2 diabetes and compared those on GLP-1 medications with those on two other diabetes drug classes. Over 18 months, the risk was 8.5 per 10,000 among GLP-1 users against 5.5 per 10,000 in one comparison group, a difference of 3.0 per 10,000 (Johns Hopkins). Against the other comparison group the difference was 3.6 per 10,000.
The study's lead author told the Boston Globe that if 10,000 people started a GLP-1, three or four of them would likely develop NAION, and that it is "still extremely, extremely rare" (Boston Globe). He also noted the effect doesn't appear limited to semaglutide and may run across the class of drugs.
European regulators reached a similar scale independently, describing "approximately one additional case of NAION per 10,000 person-years of treatment" (European Medicines Agency).
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Regulators looked at this in 2025, not this month
The timeline explains why this is coming up again in 2026.
- July 2024: a single-center study at a Boston eye hospital reported higher rates among semaglutide patients (JAMA Ophthalmology). Its own author later said in a post shared by his hospital system that, to be perfectly clear, he would not take his findings and use them to recommend that patients stop taking their medications (Boston Globe).
- June 2025: European regulators concluded NAION is "a very rare side effect of semaglutide (meaning it may affect up to 1 in 10,000 people taking semaglutide)" and required it be added to the product information (European Medicines Agency).
- February 2026: the UK reached the same conclusion, while noting "there was conflicting evidence in the literature" (MHRA). Its own reporting system had received three suspected reports against roughly 10.2 million packs dispensed over five years.
- Today: we searched the current US Wegovy prescribing information for NAION and optic neuropathy and found neither (Wegovy prescribing information). The US label hasn't been changed, while the European and UK labels have.
What the lawsuits are and are not
In December 2025 federal courts consolidated these cases into a single proceeding in the Eastern District of Pennsylvania, covering Ozempic, Wegovy and Saxenda from Novo Nordisk and Trulicity from Eli Lilly. The court describes the claims as alleging "failure to warn, design defect, and breach of warranties" (United States District Court).
A filed complaint is an allegation. No court has found that these medications cause NAION, no trial has taken place, and the litigation is still deciding which questions get answered first. Novo Nordisk has said it believes the suits are without merit and is defending them. Eli Lilly has said patient safety is its priority and that it continues to review data including on eye issues (Boston Globe).
You're hearing about it now partly because consolidation generates coverage, and partly because plaintiff law firms run advertising timed to it. Several maintain dedicated pages soliciting vision-loss claims. Advertising volume tracks litigation opportunity, not medical evidence.
What the eye doctors say to do
The American Academy of Ophthalmology and the neuro-ophthalmology society addressed this directly. They "do not support such a blanket recommendation" that patients stop, warning that "discontinuing semaglutide could pose significant health risks to patients' overall health," and they recommend shared decision-making for anyone who does develop NAION (American Academy of Ophthalmology). Their summary of the evidence: it "has not established that semaglutide causes NAION, only a potential link between the two."
- Act urgently on: sudden loss or dimming of vision in one eye, or part of your visual field disappearing. That's an emergency room or urgent eye clinic visit the same day, whatever medication you take.
- Worth raising with a prescriber: if you have diabetes, sleep apnea, low overnight blood pressure, or have been told you have a small optic nerve cup, since those raise baseline risk independently.
- Not supported: routine eye screening before starting, or stopping the medication as a precaution, though this is part of an overall health evaluation that should be repeated regularly - reach out to your clinician for recommendations.
Final Takeaway
The honest version of this story is unglamorous. A rare condition became slightly less rare in people taking a very widely used class of medication, regulators in two jurisdictions decided that was worth putting on the label, and American regulators have not yet followed. Three extra cases per 10,000 is a valid concern (especially for those with risk factors), and it sits alongside benefits that are considerably larger and better established. If your vision changes suddenly, get seen today. If it hasn't, a television advertisement isn't new medical information. Talk to your prescriber first if you have concerns rather than reading a headline and following it point blank.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
How likely is vision loss on a GLP-1?
The best current estimate is about three extra cases per 10,000 people over 18 months of treatment, on top of a background rate that already exists and is higher in people with diabetes. European regulators classify it as very rare, meaning up to 1 in 10,000.
Does the US label warn about this?
Not currently. We checked the Wegovy prescribing information and found no mention of NAION or optic neuropathy. The European and UK product information do carry it, so the same medicine comes with different written warnings depending on where you are.
Should I stop my medication because of the lawsuits?
The eye specialty societies explicitly advise against blanket discontinuation and warn it carries its own health risks. A lawsuit is an allegation rather than a finding, and no court has determined these medications cause the condition. If you have concerns, that is a conversation with your prescriber.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
Tirzepatide can make the birth control pill less reliable for 4 weeks after each dose change. Semaglutide doesn't. See what your label says.
A new patent covers a fizzy tablet meant to carry GLP-1 medicine past your stomach. See how it would work and how early it really is.
Most peptides in a wellness stack have zero human trials. See what the research shows, and the 12-year gap five basic habits produced.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.